This invention relates to improvements in health and nutrition for both animals and humans following the ingestion of specific bacteria capable of utilising lactic acid.
Under normal conditions the concentration of lactic acid (lactate) in the mammalian gut is very low despite the fact that many bacterial species, such as lactobacilli, streptococci, enterococci and bifidobacteria that reside in the intestine produce this acid in large quantities as a fermentation end product. Lactic acid is also produced by host tissues.
It has been hypothesised that the accumulation of lactic acid is normally prevented by the ability of certain other bacteria that inhabit the gut to consume lactic acid and to use it as a source of energy. The identity of the micro-organisms that are postulated to conduct this metabolic process in the mammalian large intestine has largely not previously been elucidated, Bourriaud et al (2002). Kanauchi et al (1999) revealed that a strain of Bifidobacterium longum was co-incubated with a strain of Eubacterium limosum on germinated barley feedstuff for three days there was a marked increase in acetate formed and a small increase (less than 3 mM) in butyrate formed when compared to the incubations with E. limosum alone.
In the rumen of cattle and sheep the species Selenomonas ruminantium, Veillonella parvula and Megasphaera elsdenii are regarded as the most numerous utilisers of lactate (Gilmour et al., 1994; Wiryawan and Brooker, 1995). The contribution of Megasphaera elsdenii appears to be particularly significant in the rumen, based on the high proportion of carbon flow from lactic acid to propionic acid and this species employs the acrylate pathway for this purpose (Counotte et al., 1981). Megasphaera elsdenii produces a variety of end products including propionate, butyrate, caproate and branched chain fatty acids from lactate—see Ushida et al (2002), Kung and Hession, (1995). This probably reflects the ability of this species to use lactate despite the presence of other carbon sources such as sugars, whereas Selenomonas uses lactic acid only in the absence of other energy sources. This has led to interest in the use of Megasphaera as a probiotic organism that might be added to animal (Kung and Hession, 1995; Ouwerkerk et al., 2002), or even human diets to prevent the harmful accumulation of lactic acid. In ruminant animals (cattle and sheep) accumulation of lactic acid occurs when a large amount of readily fermentable substrate (such as starch and sugars) enters the rumen. Rapid fermentation, particularly by organisms such as Streptococcus bovis, drives down the pH, creating more favourable conditions for the proliferation of lactic acid producing bacteria such as lactobacilli, and S. bovis itself. Normal populations of bacteria capable of utilising lactate (lactate utilisers) are unable to cope with the greatly increased production of lactic acid. Unaided, lactic acid may accumulate to levels that can cause acute toxicity, laminitis and death (Nocek, 1997; Russell and Rychlik, 2001).
Similar events occurring in the large intestine can also cause severe digestive and health problems in other animals, for example in the horse where high lactate levels and colic can result from feeding certain diets.
In humans lactic acid accumulation is associated with surgical removal of portions of the small and large intestine, and with gut disorders such as ulcerative colitis and short bowel syndrome (Day and Abbott, 1999). High concentrations of lactic acid in the bloodstream can cause toxicity (Hove et al., 1994), including neurological symptoms (Chan et al., 1994). Much of this lactic acid is assumed to derive from bacterial fermentation, particularly by bifidobacteria and by lactobacilli and enterococci. Lactic acid can also be produced by host tissues, but the relative contributions of bacterial and host sources are at present unclear.
Conversely, the formation of other acid products, in particular butyric acid (butyrate), is considered to be beneficial as butyric acid provides a preferred energy source for the cells lining the large intestine and has anti-inflammatory effects (Inan et al., 2001, Pryde et al., 2002). Butyrate also helps to protect against colorectal cancer and colitis (Archer et al., 1998; Csordas, 1996).
We have now established a method of isolating novel bacteria that are remarkably active in consuming lactic acid. The bacteria have been isolated from human faeces. Preferably the method allows isolation of bacteria which convert the lactic acid to butyric acid. According to this method several new bacteria that are remarkably active in converting lactic acid to butyric acid have been isolated.
One group of these bacteria is from the newly described genus Anaerostipes caccae (Schwiertz et al., 2002). Although some main characteristics of A. caccae are described in this publication, its ability to use lactate was not reported and has only recently been recognised as described herein.
The invention relates to a method for selecting a strain of lactic acid-utilising bacteria, which method comprises the steps of:
In the above method, the reference to “relatively large amounts of lactic acid” is defined as meaning the bacteria used at least 10 mM of D, L or DL lactic acid during growth into stationary phase, per 24 hours at 37° C. in YCFALG or YCFAL medium.
Preferably the strain of lactic acid utilising bacteria also produces high level of butyric acid and the method of the invention may therefore comprise an additional step of:
In the above step the reference to “relatively large quantities of butyric acid” is defined as meaning the bacteria produces at least 10 mM of butyric acid during growth into stationary phase, per 24 hours at 37° C. in YCFALG or YCFAL medium.
Preferably the strain of lactic acid utilising bacterium must be capable of converting lactate produced by another gut bacterium from dietary components such as resistant starch.
Preferably the lactic acid used in step c) is both D- and L-isomers of lactic acid.
Preferably the suitable medium to grow bacteria is nutritionally rich medium in anaerobic Hungate tubes.
Preferably the selected strain of bacteria is re-purified using nutritionally rich medium in anaerobic roll tubes.
A further aspect of the invention is a bacterial strain that produces butyric acid as its sole or predominant fermentation product from lactate and which has been isolated according to the method of the invention described above. Such novel bacterial strains include:
the bacteria Anaerostipes caccae strain L1-92 deposited at NCIMB (National Collections of Industrial, Marine and Food Bacteria in Aberdeen, United Kingdom) under No 13801T on 4 Nov. 2002 and at DSM under No 14662 on 4 Nov. 2002.
the Clostridium indolis bacterial strain Ss2/1 deposited at NCIMB under No 41156 on 13 Feb. 2003;
the bacteria strain SM 6/1 of Eubacterium hallii deposited at NCIMB under No. 41155 on 13 Feb. 2003.
Another aspect of the invention is a strain of bacteria having a 16S rRNA gene sequence which has at least 95% homology to one of the sequences shown in
Another aspect of the invention is the use of at least one of the above-mentioned bacterial strains in a medicament or foodstuff.
Another aspect of the invention is a method to promote butyric acid formation in the intestine of a mammal, said method comprising the administration of a therapeutically effective dose of at least one of the above described strains of live butyric acid producing bacteria. The bacterial strain may be administered by means of a foodstuff or suppository or any other suitable method.
Another aspect of the invention is a method for treating diseases associated with a high dosage of lactic acid such as lactic-acidosis, short bowel syndrome and inflammatory bowel disease, including ulcerative colitis and Crohn's disease, which method comprises the administration of a therapeutically effective dose of Anaerostipes caccae or at least one above-mentioned strains of live lactic acid utilising bacteria. Advantageously the strain selected may also produce a high level of butyric acid.
Further, another aspect of the invention is a prophylactic method to reduce the incidence or severity of colorectal cancer or colitis in mammals caused in part by high lactic acid and low butyric acid concentrations, which method comprises the administration of a therapeutically effective dose of at least one above identified strains of live lactic acid utilising bacteria and/or butyric acid producing bacteria mentioned above or of Anaerostipes caccae.
Another aspect of the invention is the use of live Anaerostipes caccae or at least one of the above mentioned lactic acid utilising bacteria as a medicament. Advantageously the strain chosen may produce butyric acid as its sole or predominant fermentation product from lactate. Preferably the bacteria are used in the treatment of diseases associated with high levels of lactic acid such as lactic acidosis, short bowel syndrome and inflammatory bowel disease including ulcerative colitis and Crohn's disease.
According to another aspect of the invention at least one lactate-utilising strain of bacteria as mentioned above or Anaerostipes caccae are used in combination with lactic acid producing bacteria including those such as Lactobacillus spp. and Bifidobacterium spp. or other additives or growth enhancing supplement currently used as probiotics.
The combination of strains would potentially enhance the health-promoting benefits of the lactic acid bacterium by converting its fermentation products (lactic acid alone or lactic acid plus acetic acid) into butyrate. Indeed it is possible that certain health-promoting properties currently ascribed to lactic acid bacteria might actually be due to stimulation of other species such as lactate-consumers in vivo, particularly where probiotic approaches (see below) are used to boost native populations in the gut. Furthermore the presence of the lactic acid producing bacteria in a combined inoculum could help to protect the lactate consumer against oxygen prior to ingestion.
The growth and activity of the novel bacteria may be promoted by means of providing certain growth requirements, required for optimal growth and enzyme expression to the bacteria, present in the animal or human gastrointestinal tract. These bacterial growth enhancing nutrients are often referred to as prebiotics or synbiotics.
Thus the invention provides methods to promote the growth and enzyme expression of the micro-organism and hence removal of lactate and production of butyrate in vivo, for example, via a prebiotic or symbiotic approach (Collins and Gibson, 1999).
Another aspect of the invention is a method for treating acidosis and colic in animals, particularly in ruminants and horses or other farm animals, by administration of a therapeutically effective dose of Anaerostipes caccae or at least one of the lactate utilising bacteria mentioned above. Advantageously the bacteria can be administrated as feed additives.
For the use, prevention or treatment of conditions described herein, the bacteria or prebiotic(s) or symbiotic(s) are preferentially delivered to the site of action in the gastro-intestinal tract by oral or rectal administration in any appropriate formulae or carrier or excipient or diluent or stabiliser. Such modes of delivery may be of any formulation included but not limited to solid formulations such as tablets or capsules; liquid solutions such as yoghurts or drinks or suspensions. Ideally, the delivery mechanism delivers the bacteria or prebiotic or symbiotic without harm through the acid environment of the stomach and through the rumen to the site of action within the gastro-intestinal tract.
Another aspect of the invention is the use of at least one bacterial strain mentioned above or Anaerostipes caccae in a method to produce butyric acid from lactate and acetate. The method includes the fermentation of the above described microorganism selected for both their lactic acid utilising and butyric acid producing abilities in a medium rich in lactate and acetate. The method can be used in industrial processes for the production of butyrate on a large scale.
The experimental work performed shows the following:
A faecal sample was obtained from a healthy adult female volunteer that had not received antibiotics in the previous 6 months. Whole stools were collected, and 1 g was mixed in 9 ml anaerobic M2 diluent. Decimal serial anaerobic dilutions were prepared and 0.5ml inoculated into roll tubes by the Hungate technique, under 100% CO2 (Byrant, 1972).
Bacterial strains were isolated by selection as single colonies from the nutritionally rich medium in anaerobic roll tubes as described by Barcenilla et al. (2000). The isolates were grown in M2GSC broth and the fermentation end products determined. Butyrate producing bacteria were re-purified using roll tubes as described above. Strains L1-92, S D8/3, S D7/11, A2-165, A2-181, A2-183, L2-50 and L2-7 were all isolated using this medium. Omitting rumen fluid and/or replacing the sugars with one additional carbon source such as DL lactate increased the selectivity of the roll tube medium and this medium was used to isolate strain S D6 1L/1. Strains G 2M/1 and SM 6/1 were isolated from medium where DL-lactate was replaced with mannitol (0.5%). Separately, non-rumen fluid based media routinely used for isolating Selenomonas sp., namely Ss and Sr medium (Atlas, 1997) was used to isolate other strains. Inoculating Sr medium roll tubes with dilutions of faecal samples resulted in the isolation of strain Sr1/1 while the Ss medium resulted in the isolation of strains Ss2/1, Ss3/4 and Ssc/2.
Table 1 summarises the fermentation products formed by twelve strains of anaerobic bacteria when grown under 100% CO2 in a rumen fluid-containing medium containing 0.5% lactate (M2L) or 0.5% lactate, 0.2% starch, 0.2% cellobiose and 0.2% glucose (M2GSCL) as the energy sources. Ten of these strains were isolated from human faeces as described above in Example 1. Strains 2221 and NCIMB8052 are stock collection isolates not from the human gut and are included for comparison. Table 1 demonstrates that three strains, L1-92 (A. caccae), SD6 1L/1 and SD 6M/1 (both E. hallii-related) all consumed large amounts of lactate (>20 mM) on both media examined, M2L and M2GSCL, and produced large quantities of butyric acid. A. caccae L1-92 in particular consumed large amounts of lactate and produced large amounts of butyrate. Acetate is also consumed by all three strains. The other 9 butyrate producing bacteria tested either consumed relatively small amounts of lactate, or consumed no lactate, on this medium. L-lactate concentrations were determined enzymatically and glucose concentrations were determined by the glucose oxidase method (Trinder, 1969). Analyses were conducted in a robotic clinical analyser (Kone analyser, Konelab Corporation, Finland).
*clone library sequence, uncultured (Hold et al., 2002)
+clone library sequence, uncultured (Suau et al., 1999)
#ND not determined
Table 2a shows the utilisation and production of formate, acetate, butyrate, succinate and lactate, on this occasion performed using the rumen fluid-free medium YCFA (Duncan et al. 2002) containing no added energy source, or with 32 mM lactate (YCFAL) or lactate plus 23 mM glucose (YCFALG) as added energy sources. Separately Table 2b reveals the levels of the two isomers of lactate (D and L) remaining at the end of the incubations and the concentration of glucose metabolised during the incubations. Five additional new lactate-utilising isolates were discovered using the semi-selective medium as described earlier and are included in Tables 2a and 2b, although one of these (Ss 3/4) proved to-consume a relatively small amount of lactate only on the YCFAL medium (Table 2a). Analysis of the consumption of the D and L isomers reveals that three strains (Ss2/1, Ssc/2 and Sr1/1) preferentially consumed D lactate. Partial repression of lactate consumption by glucose was observed on this medium with A. caccae L1-92, and almost complete repression for SL 6/1/1 and Ss 3/4. The previously isolated E. hallii strain L2-7 (Barcenilla et al., 2000) behaved in a similar manner to SL 6/1/1. The higher glucose concentration in this medium compared with M2GSCL is likely to explain the difference in behaviour of A. caccae compared with Table 1. The remaining five strains showed no evidence of repression of lactate utilisation in the presence of glucose although it is possible they use the glucose before switching to lactate. Butyrate levels exceeding 30 mM were obtained for four strains on YCFALG medium.
Results : The three E. hallii-related strains (L-27, SL 6/1/1, SM 6/1) and the two A. caccae strains (L1-92 and P2) were able to use both the D and L isomers of lactate during growth either on DL lactate or DL lactate plus glucose (
*clone library sequences, uncultured (Hold et al., 2002)
Cl. indolis (95%)
E. hallii
E. hallii (98%)
A. caccae (L1-92)
A. caccae (type strain)
E. hallii
*clone library sequence, uncultured (Hold et al., 2002)
Cell pellets from 1 ml cultures grown on M2GSC medium (24 h) that were resuspended in 50 μl of sterile d.H2O served as templates for PCR reactions (0.5 μl per 50 μl of PCR reaction). 16S rRNA sequences were amplified with a universal primer set, corresponding to positions 8-27 (27f, forward primer, AGAGTTTGATCMTGGCTCAG) and 1491-1511 (rP2, reverse primer ACGGCTACCTTGTTACGACTT) of the Escherichia coli numbering system (Brosius, 1978; Weisberg, 1991) with a MgCl2 concentration of 1.5 mM. PCR amplifications were performed using the following conditions: initial denaturation (5 min at 94° C.), then 30 cycles of denaturation (30 s at 94° C.), annealing (30 s at 51° C.), and elongation (2 min at 72° C.), and a final extension (10 min at 72° C.). The amplified PCR products were purified using QIA quick columns (Qiagen GmbH, Germany) according to manufacturer's instructions and directly sequenced using a capillary sequencer (Beckman) with primers 27f, rP2, 519f(CAGCMGCCGCGGTAATWC) and 519r (GWATTACCGCGGCKGCTG) (corresponding to positions 518-535 of the E. coli numbering system) and 926f (AAACTCAAAKGAATTGACGG) and 926r (CCGTCAATTCMTTTRAGTTT) corresponding to positions 906-925). Two independent PCR products were sequenced per strain.
Similarity of the 16S rRNA sequences (minimum 1444 bases) of the isolates with other organisms was compared with all sequence data in GenBank using the BLAST algorithm (Altschul, 1990).
Three lactate utilising strains, Anaerostipes caccae L1-92 and two strains of Eubacterium hallii (SM 6/1 and L2-7) were incubated alone and in co-culture with B. adolescentis L2-32 on YCFA medium modified to contain reduced casitone (0.1%) and 0.2% soluble starch as an added energy source. The inoculated tubes were incubated for 24 h at 37° C. B. adolescentis L2-32 was enumerated on Mann Ragosa Sharpe (MRS) medium containing 2.0% agar with a final concentration of 0.5% propionate and the three butyrate producing strains, were enumerated on M2 medium containing 0.5% DL lactate.
Results: In most human diets, resistant starch is considered to be the most important energy source for microbial growth in the large intestine (Topping, 2001). The major amylolytic species in the human colon are generally considered to be Bacteroides and Bifidobacterium spp. (MacFarlane, 1986; Salyers, 1977). Bifidobacteria produce acetate and lactate from carbohydrate substrates, typically in the molar ratio of 3:2. Since the lactate utilisers isolated here either do not utilise starch or utilised it weakly, as a growth substrate in pure culture, it was of interest to co-culture them with a starch-degrading Bifidobacterium strain in order to establish whether they could remove the lactate formed. The recently isolated, actively amylolytic B. adolescentis strain L2-32 was used for these experiments. As shown in Tables 3a, 3b and
B. adolescentis
Time courses were followed in batch culture for growth on glucose, lactate or glucose and lactate (
Strain SS2/1 is likely to represent a new species, since its closest relative (95% identity in 16S rRNA sequence) is the non-butyrate producing Clostridium indolis. This strain was able to use D-, but not L-, lactate following glucose exhaustion in lactate plus glucose medium (
A. caccae strain L1-92 was able to consume up to 30 mM DL lactate, along with 20-30 mM acetate during batch culture incubation for 24 hours at 37° C. with the production of >20 mM, and up to 45 mM butyrate; this occurred also when glucose was added as an alternative energy source (Table 1). Lactate or lactate plus glucose thus resulted in very much higher production of butyrate than observed with 23 mM glucose alone, when only <15 mM butyrate was formed. Furthermore none of the 74 strains screened previously by Barcenilla et al. (2000) produced more than 25 mM butyrate when tested in M2GSC medium. Lactate consumption is not a general characteristic of butyrate-producers, and six of the strains screened in Table 1 failed to consume lactate in M2GSCL medium.
Six further strains that are highly active lactate utilisers (defined for example as net consumption of at least 10 mM of lactate during growth to stationary phase or for 24 hours in YCFALG or YCFAL medium at 37° C.—see Table 2a) were obtained following deliberate screening of new human faecal isolates for lactate utilisation. At least two of these (SL 6/1/1 and SM 6/1—Tables 1, 2) are related to Eubacterium hallii. (Table 2a), based on determination of their 16S rDNA sequences. These isolates again consume large quantities of lactate and produce high levels of butyrate in vitro. With one exception where considerable glucose repression occurred (strain SL 6/1/1), significant lactate utilization occurred in the presence of glucose (Table 2). Three strains (Ss 2/1, Sr 1/1 and Ssc/2) showed preferential utilization of D-lactate, whereas the two E. hallii-related strains SM 6/1, SL 6/1/1 and A. caccae L1-92 utilise both isomers (Table 2b). The two stereoisomers differ in their toxicity in the human body, with the D-isomer being regarded as the more toxic (Chan et al., 1994, Hove et al., 1995). The present invention thus provides a means of utilising both D and L lactate isomers or preferentially utilising D-lactate in preference to L-lactate.
A. caccae and newly isolated bacteria related to E. hallii and Cl. indolis were shown to consume up to 30 mM DL, D or L lactate, along with 20-30 mM acetate during batch culture incubation and convert this energy in to production of at least 20 mM, and up to 45 mM butyrate. Furthermore, these strains were shown to convert all of the L-lactate produced by a starch-degrading strain of Bifidobacterium adolescentis into butyrate when grown in culture. This is the first documentation demonstrating the conversion of lactate to butyrate by human colonic bacteria, some of which are likely to be new species.
Number | Date | Country | Kind |
---|---|---|---|
0307026.5 | Mar 2003 | GB | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/GB04/01398 | 3/29/2004 | WO | 11/9/2005 |